Furthermore, METTL5 was shown to positively control PD‐L1 expression, the ligand of a T cell inhibitory receptor, in human HCC lines.[68] Besides PD‐L1, our clinical data demonstrated that expression levels of multiple IFN‐related genes are lower in METTL5‐High tumors from OC patients. This evidence concerns the gene METTL5 and hepatocellular carcinoma.